Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4717471 | 0.92 | BRD4 (0.33) | KDM4EBRD4PARP1MEN1KMT2A | |
| Butyric Acid SCHEMBL4169377 | 0.90 | KDM4E (0.34) | KDM4EGAAPARP1MEN1KMT2A | |
| Butyric Acid SCHEMBL4162510 | 0.85 | PKM (0.37) | KDM4EGAABRD4PARP1 | |
| Butyric Acid SCHEMBL4163999 | 0.84 | KDM4E (0.47) | KDM4EGAAMEN1KMT2A | |
| Butyric Acid SCHEMBL4165214 | 0.84 | ALOX5AP (0.36) | MEN1KMT2A | |
| Butyric Acid SCHEMBL4161012 | 0.79 | ALDH1A1 (0.36) | KDM4EBRD4MEN1KMT2A | |
| SCHEMBL4157906 | 0.78 | GAA (0.34) | KDM4EGAAMEN1KMT2A | |
| Butyric Acid SCHEMBL4156383 | 0.77 | KDM4E (0.45) | KDM4EGAAMEN1KMT2A | |
| SCHEMBL3245575 | 0.77 | HPGD (0.34) | KDM4EMEN1KMT2A | |
| Butyric Acid SCHEMBL4171746 | 0.74 | PKM (0.37) | KDM4EGAABRD4PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | claimed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | claimed |
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | MAP3K1, MAP3K2, MAP3K7 | KDM4E 1970/4885GAA 3035/4885BRD4 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.